Special Issue "G‐quadruplex Ligands: Recent Advances"
Deadline for manuscript submissions: closed (25 November 2023) | Viewed by 1424
Interests: cancer; G-quadruplex; aging
G-quadruplexes (G4s) are guanine-rich non-canonical secondary structures of nucleic acids which were discovered in vitro almost a half century ago. From the early 1980s onward, these structures have also been identified in eukaryotic cells, first at the level of telomeres and more recently in regulatory regions of certain genes.
Due their involvement in numerous biological processes and in the pathogenesis of several disease, including cancer, the interest in G4s and their targeting has undergone exponential growth over the last few years. Notably, G4 ligands constitute a large family of heterogeneous molecules which exert their functions through recognition, binding and stabilization of G4 structures. In terms of anti-cancer activity, the efficacy of G4 ligands can be attributed to their capability to inhibit telomerase activity (long-term effects) and induce DNA damage and/or modulation of cancer-related genes (short-term effects). Interestingly, while the knowledge concerning the structural organization of G4s has been extensively characterized, the functions, the potential application of these structures and the development of novel G4s are still active research topics worthy of further investigation.
Dr. Zizza Pasquale
Dr. Sara Iachettini
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- genomic stability
- DNA damage